德国拜耳生产的口服抗凝药拜瑞妥效果怎么样？

How effective are the oral anticoagulants produced by Bayer in Germany?

The long-term therapeutic effect and safety of different doses of German Bayer's Xarelto (20 mg, 10 mg) and aspirin on venous thromboembolism were compared.

Antithrombotic therapy is an important means to prevent the recurrence of venous thrombosis. If anticoagulant therapy is discontinued, the recurrence rate of venous thromboembolism in the first year is as high as 10%. The purpose of this study was to compare the clinical efficacy and safety of antithrombotic therapy at 20 mg, 10 mg of Xarelto, and 100 mg of aspirin daily for 12 months.

In a randomized, double-blind, controlled study, the clinical trial was divided into 3 groups. The first group of 1107 patients took 20 mg of Xarelto, the second group of 1127 patients took 10 mg of Xarelto, and the third group of 1131 patients took 100 mg of aspirin. These patients had completed 6 to 12 months of initial anticoagulant therapy.

After 12 months of continuous use, the recurrence rate of venous thrombosis in the aspirin group was 4.4%. The recurrence rates of Xarelto 20 mg and 10 mg were significantly lower than those in the aspirin group, which were 1.5% and 1.2% respectively. Comparing the three groups, there were very few patients who experienced severe bleeding after taking the drug, which were 0.3%, 0.4% and 0.5% respectively. There was no statistical difference between the three groups. The clinically relevant non-bleeding events between the 3 groups were 2.7, 2.0, and 1.8 respectively, and there was also no statistical difference.

For patients with venous thrombosis who have completed 6 to 12 months of treatment and need to continue treatment and who are clinically in equilibrium, using German Bayer 20 mg or 10 mg continuous anticoagulation to treat venous thromboembolism is more effective than 100 mg aspirin, with a significantly lower recurrence rate than aspirin, and does not increase the incidence of bleeding. The feasibility of a low dose (10 mg) in the treatment of venous thromboembolism has also been demonstrated.

Recommended related hot articles: /newsDetail/88190.html